

Ganga Pharmaceuticals Limited

CIN: L99999MH1989PLC053392

Regd. Office: Gangatat, Dhanvantri Marg, Gopcharpada, Virar (E), Palghar - 401305
Phone: 9834613142 | Website: www.ayurvedganga.com | Email: ayurvedganga@gmail.com

November 08, 2024

The Manager (Listing)
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Fort
Mumbai 400001

Ref. Scrip code: 539680

Sub.: Outcome of the Board Meeting pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 held on Friday, November 08, 2024

Dear Sir/Madam,

With reference to the captioned subject and in compliance with the Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, this is to inform you that the Board of Directors of the Company at its Meeting held today i.e. Friday, November 08, 2024 inter-alia have considered and approved the Un-audited financial results of the Company for the half year ended on September 30, 2024.

A copy of the un-audited Financial Results adopted and approved by the Board of Directors for the half year ended on September 30, 2024 along with limited review report of the Auditors thereon is attached herewith.

The Meeting was commenced at 4.30 p.m. and concluded at 5.00 p.m.

Please take the same on your records and suitably disseminated at all concerned.

Thanking you,

Yours faithfully,
For Ganga Pharmaceuticals Limited

SHARMA  Digitally signed by
SHARMA BHARAT B
Date: 2024.11.08
17:04:35 +05'30'

Bharat Sharma
Managing Director
DIN: 00077026
Email ID: bharat.sharma@gangapharma.in

Encl.: As above



**INDEPENDENT AUDITORS LIMITED REVIEW REPORT ON
UNAUDITED FINANCIAL RESULTS OF THE COMPANY FOR
THE HALF YEAR ENDED 30.09.2024 PURSUANT TO THE
REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS
AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015
(AS AMENDED)**

To,

**The Board of Director
Ganga Pharmaceuticals Ltd.**

We have reviewed the accompanying statement of unaudited financial results of **Ganga Pharmaceuticals Ltd** for the period ended on 30th September, 2024. This Statement is the responsibility of the Company's Management and has been approved by the Board of Director. Our responsibility is to issue a report on these financial statements based on our review.


We conducted our review of the Statement in accordance with the Standard on Review Engagements (RE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Yours Faithfully,

For BANKA & BANKA

CHARTERED ACCOUNTANTS
ICAI FIRM REG.NO.100979W



(Pradeep P. Banka)

Partner

Membership No.: - 038800

UDIN: - 24038800BKAGNO1903

Mumbai :- 08/11/2024

GANGA PHARMACEUTICALS LIMITED

CIN: L99999MH1989PLC053392


REGISTERED OFFICE ADDRESS : GANGATAT, DHANVANTARI MARG, GOPCHAR PADA, VIRAR (EAST)-401 305.

Tele No.+91-250-6098444 Email id: gangapharmaltd@gmail.com , Website: www.ayurvedganga.com

Statement of Un-Audited Financial Results for the Half and Year ended 30 September,2024.

		Rs.in thousand				
Sr. No	Particulars	Figures for the half year ended on			Financial year ended on	Financial year ended on
		30-09-2024	31-03-2024	30-09-2023	31-03-2024	31-03-2023
		(Un-Audited)	(Audited)	(Un-Audited)	(Audited)	(Audited)
1	INCOME FROM OPERATIONS					
	(a) Revenue from operations	13,112.74	14,164.40	13,193.36	27,357.77	25,863.33
	(b) Other Income	2,929.25	1,506.69	888.24	2,394.93	2,981.93
	Total Income	16,041.99	15,671.09	14,081.60	29,752.69	28,845.26
2	Expenses:					
	(a) Cost of Materials consumed	7,021.93	6,869.63	6,321.00	13,190.63	13,421.15
	(b) Purchase of stock in trade	-	-	-	-	-
	(c) Change in inventories of finished goods & packing Material	(833.43)	(643.87)	(89.00)	(732.87)	(1,026.98)
	(d) Employee Benefit Expenses	2,879.14	3,280.25	2,517.80	5,798.05	5,110.36
	(e) Finance Cost	894.66	908.43	937.86	1,846.28	1,935.88
	(f) Depreciation and Amortization Expense	239.89	206.03	286.63	492.66	562.08
	(g) Other Administrative Expenses	5,167.61	4,604.97	3,920.15	8,525.12	8,311.56
	Total Expenses	15,369.80	15,225.44	13,894.43	29,119.87	28,314.05
3	Profit/(Loss) before Tax (1-2)	672.18	445.66	187.17	632.82	531.21
4	Tax Expenses					
	(a) Current Tax	391.26	107.50	57.24	164.75	161.47
	(b) Deferred Tax	40.29	(34.20)	32.30	1.90	(23.32)
5	Net Profit / (Loss) for the period (3-4)	240.64	303.96	162.23	466.18	393.07
6	Other Comprehensive Income				-	-
7	Paid - Up equity share capital (Equity Share of Rs. 10/- each)	483.65	483.65	406.15	483.65	406.15
8	Earning per equity share (Rs.)					
	(1) Basic	0.050	0.070	0.040	0.110	0.097
	(2) Diluted	0.050	0.030	0.040	0.071	0.097

For and on behalf of the Board of Directors
Ganga Pharmaceuticals Limited


Bharat Sharma
Managing Director
DIN : 00077026
Place: Virar, Palghar
Date : 8th November, 2024



GANGA PHARMACEUTICALS LTD

CIN: L99999MH1989PLC053392

Registered Office: Gangatat, Dhanvantari Marg, Gopcharpada, Virar (East), Palghar -401 305.

Tele Nos.:0250-6098333/444 ; Website: www.ayurvedganga.com; Email id:gangapharmaltd@gmail.com

Statement of Un-Audited Assests and Liabilities as at 30th September, 2024

		Rs.in thousand	
	Statement of Assets and Liabilities Particulars	As at (30-09-2024)	As at (31-03-2024)
A	EQUITY AND LIABILITIES		
	(1) Shareholders Funds:		
	(a) Share Capital	48,365.00	48,365.00
	(b) Reserve & Surplus	16,188.80	15,948.16
	(C) Money received against share warrants	6,212.50	6,212.50
	(2) Non-Current Liabilities		
	(a) Long-Term Borrowings	5,088.43	3,947.55
	(b) Deferred Tax Liabilities (Net)	88.21	47.92
	(c) Other Long Term Liabilities	-	-
	(d) Long Term Provisions	-	-
	(3) Current Liabilities		
	(a) Short-term borrowings	10,530.31	9,632.55
	(b) Trade payables		
	i) Total outsatnding dues of micro enterprises and small enterprises	323.05	-
	ii) Total outsatnding dues of creditors other then micro enterprises and small enterprises	1,855.80	999.32
	(c) Other current liabilities	707.71	1,158.04
	(d) Short-term provisions	751.99	164.75
	Total	90,111.80	86,475.80
B	ASSETS		
	(1) Non - Current assets		
	(a) Fixed Assets	5,963.87	6,124.85
	(b) Non-current investments	-	850.00
	(c) Deferred tax assets (net)	-	-
	(d) Long term loans and advances	-	-
	(e) Other Non-current assets	14,407.19	21,997.96
	(2) Current assets		
	(a) Current Investment	-	-
	(b) Inventories	11,726.75	12,413.40
	(c) Trade receivables	9,990.57	9,231.98
	(d) Cash and cash equivalents	4,770.44	298.30
	(e) Short-term loans and advances	19,749.67	15,066.23
	(f) Other current assets	23,503.31	20,493.09
	Total	90,111.80	86,475.80

For and on behalf of the Board of Directors
Ganga Pharmaceuticals Limited



Bharat Sharma
Managing Director
DIN : 00077026

Place: Virar, Palghar
Date : 8th November, 2024

GANGA PHARMACEUTICALS LIMITED

Cash Flow Statement for the half year ended 30th September 2024.

	Half Year ended 30th September 2024 (Rs. In '000')	Half Year ended 30th September 2024 (Rs. In '000')	Year ended 31st March 2024 (Rs. In '000')	Year ended 31st March 2024 (Rs. In '000')
A. Cash flow from operating activities:				
Net profit before tax as per Profit and Loss Account.		672.18		632.83
Adjustment to reconcile profit before tax to net cash flows :				
Depreciation and amortisation expense	239.89		492.66	
Interest on advance & deposit recd	(1,048.20)		-2,394.93	
Finance cost	894.66		1,810.24	
Profit on sale of Investment	(1,881.05)			
		<u>(1,794.70)</u>		<u>-92.03</u>
Operating profit before working capital changes		<u>(1,122.51)</u>		<u>540.80</u>
Movements in working capital:				
(Decrease) / Increase in trade payables	1,179.54		-4,809.26	
(Decrease) / Increase in other liabilities	(450.33)		101.92	
(Decrease) / Increase in Short term borrowing	897.76		-2,286.18	
(Decrease) / Increase in Short term Provision	587.23		3.29	
(Increase) / Decrease in trade receivables	(758.60)		-339.60	
(Increase) / Decrease in other current assets	(3,010.22)		-4,387.71	
(Increase) / Decrease in Short-term loans and advances	(4,683.44)		-707.04	
(Increase) / Decrease in Inventories	686.65		-585.83	
		<u>(5,551.41)</u>		<u>-13,010.41</u>
Cash generated from operations		<u>(6,673.92)</u>		<u>-12,469.62</u>
Taxes paid		(391.26)		-170.01
Net cash from operating activities		<u>(7,065.18)</u>		<u>-12,639.62</u>
B. Cash flow from investing activities:				
Purchase of fixed assets	(78.92)		-223.52	
Advances given	-		-	
Proceeds from Deposit maturity during the year	7,590.77		-875.42	
Proceeds from sale of Investment (Incl.Cost)	2,731.05		-	
Investment made during the year	-		-	
Interest received	1,048.20		2,394.93	
Net cash used in investing activities		<u>11,291.10</u>		<u>1,295.99</u>



GANGA PHARMACEUTICALS LIMITED
Cash Flow Statement (Contd.)

	Half Year ended 30th September 2024 (Rs. In '000')	Half Year ended 30th September 2024 (Rs. In '000')	Year ended 31st March 2024 (Rs. In '000')	Year ended 31st March 2024 (Rs. In '000')
C. Cash flow from financing activities:				
Repayment of borrowings	-		-2,398.25	
Proceeds from borrowings	1,140.88		-	
Proceeds from Issue of Shares and Warrants (net of Issue Expenses)	-		15,560.41	
Finance cost	(894.66)		(1,810.24)	
Net cash used in financing activities		246.22		11,351.93
Net increase / (Decrease) in cash and cash equivalents		4,472.14		8.29
Cash and cash equivalents as at the beginning of the year		298.30		290.01
Cash and cash equivalents as at the end of the year		4,770.44		298.30
Cash and cash equivalent comprises of :				
Cash in hand		181.93		177.89
Balance with banks		4,588.51		120.40
Total		4,770.44		298.30

Notes:

- 1 The above Cash Flow Statement has been prepared under the "Indirect Method" as set out in the Notified Accounting Standard - 3 on Cash Flow Statements.
- 2 Figures in bracket indicate cash outgo.
- 3 Previous years' figures have been regrouped/rearranged to conform with current years' classifications.

As per our report of even date

For and on behalf of the Board of Directors of
Ganga Pharmaceuticals Limited



Bharat Sharma
Managing Director
DIN : 00077026



Place : Mumbai

Date: 8th Nov 2024

Notes:

- 1 The above results for the half year ended 30-09-2024 have been reviewed by the Audit Committee in their meeting held on 8th Nov 2024 and approved by the Board of Directors in their meeting held on 8th Nov 2024.
- 2 The Financial Results of the company have been prepared in accordance with Accounting Standards (AS) as prescribed under section 133 of the companies Act 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014.
- 3 Revenues from Operations is net of trade Discounts/ Trade incentives.
- 4 In accordance with AS 17 on "Operating Segments", the company operated in one business segment viz. Ayurveda Business and hence segment information is not required to be furnished.
- 5 In the previous year, the company had raised amounts to Rs. 1.71 crores by issue of 7,75,000 Equity Shares at Face Value of Rs. 10 each at premium of Rs.4 and by issue of 17,75,000 Shares warrants at Face Value of Rs. 10 each at premium of Rs.4 subscribe @25% on preferential allotment basis. In line with the objects of the issue, the funds have been utilized to the extent of Rs. 0.95 crores till 31st March 2024 and Rs.0.27 have been utilized till 30th September 2024 for the purpose it was raised and the balance is parked in current account of the Company.
- 6 Figures of the corresponding previous period have been regrouped/rearranged wherever necessary to confirm to the classification of the current period.

For and on behalf of the Board of Directors
Ganga Pharmaceuticals Limited


Bharat Sharma
Managing Director
DIN : 00077026
Place: Virar, Palghar
Date : 8th November, 2024

